Mccauley; Thomas

Patent Applications and Registrations

Patent applications and USPTO patent grants for Mccauley; Thomas.The latest application filed is for "composition and methods for treatment of ornithine transcarbamylase deficiency".

Company Profile

5.8.15

Mccauley; Thomas - Cambridge MA
McCauley; Thomas - Lexington MA
MCCAULEY; Thomas - Arlington MA
McCauley, Thomas - Somerville MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase Grant 11,357,832 - Barbier , et al. June 14, 2	2022-06-14
Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency App 20220072152 - Askew; Kim ; et al.	2022-03-10
Composition and methods for treatment of ornithine transcarbamylase deficiency Grant 11,167,043 - Askew , et al. November 9, 2	2021-11-09
Treatment Of Cognitive Impairment Of Hunter Syndrome By Intrathecal Delivery Of Iduronate-2-sulfatase App 20200376093 - Barbier; Ann ; et al.	2020-12-03
Cns Delivery Of Therapeutic Agents App 20200113981 - Calias; Pericles ; et al.	2020-04-16
Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase Grant 10,568,941 - Barbier , et al. Feb	2020-02-25
Ocular Distribution And Pharmacokinetics Of Lifitegrast Formulations App 20200009130 - CHUNG; Jou-Ku ; et al.	2020-01-09
CNS delivery of therapeutic agents Grant 10,456,454 - Calias , et al. Oc	2019-10-29
Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency App 20190192688 - Askew; Kim ; et al.	2019-06-27
Treatment Of Cognitive Impairment Of Hunter Syndrome By Intrathecal Delivery Of Iduronate-2-sulfatase App 20180071371 - Barbier; Ann ; et al.	2018-03-15
Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase Grant 9,682,129 - Barbier , et al. June 20, 2	2017-06-20
Subcutaneous administration of iduronate-2-sulfatase Grant 9,603,908 - Xie , et al. March 28, 2	2017-03-28
Cns Delivery Of Therapeutic Agents App 20170042978 - Calias; Pericles ; et al.	2017-02-16
CNS delivery of therapeutic agents Grant 9,283,181 - Calias , et al. March 15, 2	2016-03-15
Methods Of Treating B2-bradykinin Receptor Mediated Angioedema App 20160030416 - Leach; Kevin ; et al.	2016-02-04
Treatment Of Cognitive Impairment Of Hunter Syndrome By Intrathecal Delivery Of Iduronate-2-sulfatase App 20150328289 - BARBIER; Ann ; et al.	2015-11-19
Subcutaneous Administration Of Iduronate- 2-sulfatase App 20150086526 - Xie; Hongsheng ; et al.	2015-03-26
Methods And Compositions For Cns Delivery Of B-galactocerebrosidase App 20130295071 - Salamat-Miller; Nazila ; et al.	2013-11-07
Cns Delivery Of Therapeutic Agents App 20120003202 - Calias; Pericles ; et al.	2012-01-05
Methods And Compositions For Cns Delivery Of B-galactocerebrosidase App 20110318324 - Salamat-Miller; Nazila ; et al.	2011-12-29
Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics App 20090053138 - Preiss; Jeffrey R. ; et al.	2009-02-26
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics App 20040253679 - Epstein, David ; et al.	2004-12-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.